Halofenate, 2-aceto amidoethyl (p-chlorophenyl) (m-triftuoromethylphenoxy) acetate, is an investigational hypoJipidemic drug which has also been demonstrated to be an effective uricosuric agent. Our study was designed to compare the effects of halofenate and probenecid on serum lipid and uric acid values and on certain monitoring parameters in adults with hyperlipidemia and uricemia. We also sought to determine whether halofenate and probenecid induced different responses in serum cholesterol, triglycerides and uric acid in
patients with baseline levels of cholesterol, triglycerides, uric acid and percent ideal body weight above the median value for the group and in patients with baseline levels for these parameters below the median value for the group.
Materials and methods
Patients between the ages of 21 and 65 yr were selected on the basis of elevation of both serum uric acid (7 mg/ I 00 ml or over for men and 6 mg/ 100 ml or over for women) and serum lipids (mean untreated serum cholesterol of 275 mg/ I 00 ml or over and/or mean untreated fasting serum triglycerides of 150 mg/100 ml or over) and their ability to participate in a 56-wk study. The following led to exclusion from the study: pregnancy, lactation, a history of uric acid renal stone formation, gouty nephropathy, requirement for long-term salicylate therapy, serious alcoholism, significant impairment of liver or renal function, recent severe or poorly controlled cardiac disease, any severe disease, and a history of significant prior adverse reaction to probenecid or halofenate. Drug therapy was preceded by a control period of 8 wk during which patients were seen at 2-wk intervals and baseline clinical and laboratory data were obtained. All patients had careful ophthalmologic examinations during the control period and again after 48 wk of treatment.
Patients were separated into four diagnostic categories as follows: (I) patients under 55 yr without clinical evidence of atherosclerosis; (2) patients under 55 yr with atherosclerotic compli· cations; (3) patients 55 yr and over with no atherosclerotic complications; (4) patients 55 yr and over with atherosclerotic complications. Twenty-six patients who met the criteria for entry into the study were randomly assigned to receive either halofenate or probenecid. The drugs were supplied as identical-appearing 500-mg tablets. Dosage was based on the pa- tient's actual weight as follows: under 60 kg, itors, and hypolipidemic drugs were not per-500 mg once daily; 60 to 99 kg, 1,000 mg once mitted. Other medication needed for the padaily; 100 kg and above, 1,500 mg once daily.
tient's well-being were continued throughout Patients were seen 2 and 4 wk after the starting the study. Changes in such medication during of treatment and at 4-wk intervals thereafter. At the study were noted. No specific dietary regieach 4-wk visit they were required to return all men was prescribed, but an attempt was made unused medication. The tablets were counted to have each patient follow the same diet and recorded to document compliance to the throughout the study. Diet histories were obprescribed schedule. Downward dosage adtained from most patients at the start and comjustment was permitted in the event of minor pletion of the study. intolerance or side effects.
At each visit, patients' weight, blood presUricosuric drugs, xanthine oxidase inhibsure, pulse, liver size, and drug tolerance were 15 Hemoglobin, hematocrit, white blood cell count (WBC) and differential, platelet count, and urine were analyzed by standard techniques. Serum glucose, blood urea nitrogen, serum bilirubin, serum glutamic oxaloacetic transaminase (SOOT), (lactic dehydrogenase) (LDH) , serum alkaline phosphatase, creatine phosphokinase (CPK) , total serum protein, and serum albumin were determined by AutoAnalyzer (SMA 12-60),31
Halofenate and probenecid 343 While 13 subjects began the study in each treatment group, one subject in the probenecid group left after 12 wk because of recurrent stomatitis possibly aggravated by probenecid and one in the halofenate group left after 4 wk because of fever, shaking chills, gingivitis, and marked neutropenia. He was hospitalized elsewhere and halofenate was discontinued; WBC returned to normal within 12 days. Results reported here are for the 24 patients who completed the 56-wk study. To determine whether the drugs had significant effects on serum triglycerides, cholesterol, or uric acid or on biochemical, hematologic, or other parameters, baseline data were averaged. ("Baseline" will refer to the period of placebo administration, i.e., wk 0 to 8.) The 48-wk treatment period was then arbitrarily divided into weeks 10 to 24 (period A), weeks 28 to 40 (period B), and weeks 44 to 56 (period C). Table II indicates that there was a decline in serum triglycerides (11.7%) between the baseline period and period A in the group taking halofenate (group H). This decline was sustained throughout the entire treatment period and averaged 12.7% for the entire period (p = tFigures in parentheses = % of baseline value.
Results

Baseline studies (intergroup comparisons).
:j:Paired t tests were performed on log· transformed data. §NS: not significant; p > 0.05.
0.04). (See below for analysis of factors re-
lating to the wide variability in individual triglyceride responses in group H.) Halofenate did not induce a significant change in serum cholesterol concentration but it did induce a decline in serum uric acid concentration of 31.3% in period A. This decline was sustained throughout the remaining period, averaging 33.6% (p < 0.0001). A mild gradual increase in weight was noted, reaching 3.1 % in period C and averaging 2.2% for the entire treatment period (p = 0.04).
The effect of halofenate on various biochemical, hematologic, and hemodynamic parameters and its effect on ophthalmologic and electrocardiographic status were tested with the use of paired t test analysis (or contingency table type of analysis in the case of categoric data). In patients receiving halofenate, significant reductions occurred (Table III) in the following parameters in one or more of periods A, B, and C: fasting serum glucose (average 8.7% reduction, periods A to C); total protein (2.9% decline in period B); serum albumin (13.2% decline, periods A to C); bilirubin (51% decline, periods A to C); hematocrit (3.0% decline in period C); hemoglobin (6.8% decline in periods B and C); systolic blood pressure (3.8% decline in period A); diastolic blood pressure (4.8% decline in periods A to C). Serum LDH was significantly elevated (average of 13.3%) throughout the entire treatment period. There were no significant differences in the other biochemical or hematologic parameters or in the ophthalmologic and electrocardiographic findings.
In the probenecid group there were no significant changes in ideal weight or in serum triglycerides or cholesterol. As expected, probenecid induced a prompt decline in serum uric acid in period A which was sustained throughout periods Band C, averaging 30% for the entire treatment period (p < 0.0001).
In the patients receiving probenecid, there were significant reductions (Table III) in serum albumin (7.5% decline, periods A to C), hemoglobin (4.5% decline, periods B and C), and systolic and diastolic blood pressure (3% decline in period B). There were no significant differences in the other biochemical or hematologic parameters or in the ophthalmologic and electrocardiographic parameters.
Aside from leukopenia in one patient on halofenate and stomatitis in one patient on probenecid described above, there were no significant adverse effects during the study.
Comparison of the effects of halofenate and probenecid on certain parameters (between-group comparisons), To determine whether halofenate and probenecid exerted significantly different effects on serum triglycerides, cholesterol, and uric acid, the analytic approach involved a one-way analysis of covariance with one covariate. In this approach, the mean levels of triglycerides, cholesterol, uric acid, and percent ideal weight for each subject were computed for the baseline period and period C. The difference between the two time periods for each parameter was computed, producing new variables: Ll triglycerides (Ll TG), Ll cholesterol (LlCH), Ll uric acid (LlUA), and Ll percent ideal weight (Ll %IW), respectively.
Because changes in percent ideal weight over time might affect serum triglyceride, 6 cholesterol,41 or uric acid,35 one-way analysis of covariance was performed with the use of Ll TG (or LlCH, or LlUA) as the dependent variable, Ll%IW as the covariate, and the drug type as the factor to be considered. In other words, the change in serum triglyceride, cholesterol, or uric acid concentration (LlTG, LlCH, LlUA) from baseline period to period C is compared, adjusting for possible changes in percent ideal weight between the same two time periods and testing whether the changes with halofenate were significantly different from those with probenecid.
These analyses revealed that there was no significant difference between halofenate and probenecid in their effects on serum cholesterol or uric acid in the two groups. There was, however, a significant difference (p = 0.006) in the case of serum triglycerides, with the halofenate group exhibiting lower values.
The same analytic approach was next adopted to determine whether intergroup differences in serum triglyceride concentration were noted between baseline and period A and baseline and period B and between periods A and B, A and C, and Band C. There were no significant differences in the effects of halofenate and probenecid in any of these shorter time
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and Therapeutics period comparisons. Thus it appears that the difference in the effect of the two drugs on serum triglycerides becomes more marked with time, reaching statistical significance in 44 to 56 wk of treatment. Both drugs reduced the level of serum triglycerides initially, but the halofenate group maintained this reduced level while the serum triglycerides in the probenecid group rose above baseline after period A.
Comparison of halofenate with probenecid: Effects on other parameters (between-group comparisons)
, With the use of the same approach, analyses were conducted to compare the effects of halofenate and probenecid on those other biochemical, hematologic, and hemodynamic parameters described above in which inspection of the within-group mean values for each parameter followed over time suggested the possibility of differential effect.
Analyzing the effects on serum LDH, the mean difference (baseline to period C) for group H was 20.5 IU (12.1% increase), while that for the probenecid group (group P) decreased 34.4 IU «p = 0.0005) with MannWhitney U test, since the data were skewed). With the use of the same approach, betweengroup comparisons of fasting serum glucose, total protein, albumin, bilirubin, hematocrit, hemoglobin, and systolic and diastolic blood pressure revealed no statistically significant differences.
Relationship of initial serum lipid, uric acid, or percent ideal weight level to subsequent responses to drug therapy (between-group analyses)
, To determine whether the drug effect on serum triglycerides, cholesterol, or uric acid might be a function of the initial level of these variables (or of percent ideal weight), the effects of halofenate and probenecid were compared. The median baseline levels (within groups Hand P separately) of serum triglycerides, cholesterol, uric acid, and percent ideal weight were determined, and then, within each drug group, each individual was assigned to either the high or the low stratum. Finally, a series of two-way analyses of covariance were performed on the dependent variables LlTG, LlCH, and LlUA with one covariate (Ll%IW) and two factors (level = high or low and drug type = H or P). These analyses* revealed: (1) the expected "drug effect" due to halofenate (Table II) when the response variable was serum triglycerides and baseline was compared with period C; (2) a differential high-low effect was noted when the variable was serum uric acid and again when the variable was percent ideal weight. In the former, a differential response was noted in two response variables (serum triglycerides and uric acid), while in the latter a differential response was noted only in serum triglycerides. These responses were evident when baseline and period C data were compared and also when baseline data were compared with all treatment periods combined. In all cases, there was a greater effect (a greater decline) in the "high" halofenate group than in the "low" halofenate group. Likewise, there was a greater decline (or a lesser increase) in the "high" probenecid group than in the "low" probenecid group. This was noted when both uric acid and percent ideal weight were the segregating variables. The greatest difference in halofenate effect was noted when percent ideal weight was the segregating variable; in the baseline/period C comparison, the "high" halofenate group experienced a 25.5% decline in serum triglycerides, whereas in the "low" halofenate group there was a 2.7% rise in serum triglycerides. When the halofenate group was segregated on baseline serum uric acid level, there was a 22.6% reduction in the "high" group, whereas there was a 2.4% reduction in serum triglycerides in the "low" group between baseline and period C.
Relationship of certain dietary and disease variables to percent change in triglycerides and percent change in ideal body weight (intragroup comparisons),
Because the average percent reduction in serum triglycerides in group H was considerably less than that reported by others and because of the wide variability in the Il TO (baseline to period C; range = -48.3 % to + 34.1 %), certain other variables which might also affect serum triglyceride level were examined by scatter plots and analysis of correlation coefficients. In 
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group H, there was a correlation between %IlTO and % calories from alcohol; in group P there was a correlation between %IlTO and %IlIW (p < 0.05 for both).*
Discussion
Others have reportedl -5 , 9, 17, 21-22, 24, 26, 29, 31, 33, 36, 38-40, 46, 47 that the principal clinically significant effects of halofenate were on fasting serum triglyceride and uric acid concentrations. In our study, the halofenate group averaged a 12.7% decline in serum triglycerides (range, -48.3% to +34.1%) which was evident within 2 wk and sustained over 48 wk. The decline in serum triglycerides was generally dependent (though not in a linear fashion) on the initial percent ideal body weight and the initial serum uric acid level. It was not significantly related to the initial serum triglyceride or to cholesterol concentration. While careful efforts were made to assure constant weight in subjects throughout the study and while the average weights remained wi thin ± 10 pounds of starting weight in 87% of subjects, even this weight change had an effect on the triglyceride values. Analysis of individualll TO values revealed a significant relationship to change in weight in group P but not in group H (suggesting that the effect of halofenate overrides the expected relationship between Il TO and IlIW) and in group H to percent alcohol intake in baseline.
Halofenate induced a 31 % decline in serum uric acid which was evident within 2 wk and sustained over the entire treatment period. The uric acid effect was essentially identical to that achieved with probenecid. Other studies 22 , 24, 33, 36, 46 have demonstrated that the decline in serum uric acid concentration results from the uricosuric effect of halofenate. Our study indicates that the degree of reduction in serum uric acid with both halofenate and probenecid is related to the initial serum uric acid concentration and in the probenecid group also correlates with the baseline percent ideal weight.
Halofenate induced a transitory decline in serum cholesterol (6.0%) at 2 wk, followed by an immediate return to baseline resulting in no significant overall effect.
Changes were noted (on intragroup analysis) in the halofenate group in fasting serum glucose, protein, albumin, bilirubin, hematocrit, hemoglobin, systolic and diastolic blood pressures (declines), and serum LDH (elevation) and in the probenecid group in serum albumin, hemoglobin, and systolic and diastolic blood pressures (declines). When intergroup comparisons were performed, the only significant difference was in serum LDH (with halofenate producing a greater percent increase).
The reduction of serum glucose by halofenate was shown not to be related to the taking of sulfonylurea drugs by patients in the halofenate group.25 (Only one subject was taking tolbutamide; exclusion of data on the subject did not materially alter the serum glucose responses.) The lowered serum glucose may result from a reduced insulin/glucagon ratio. 13 The lowering of serum bilirubin concentration in the halofenate group already reported by others 2 1. 22. 33. 40 was of similar magnitude and is considered to be due to the vigorous binding of halofenate to albumin l2 . 14, 20. 42, 43, 45 which in tum decreases the binding of organic compounds such as bilirubin,23. 44, 48 resulting in increased bilirubin clearance and decreased serum bilirubin concentration.
The effect of halofenate on serum protein and albumin concentrations may be due to its effect in reducing amino acid incorporation into protein, as shown by Homcy and Margolis 19 with the use of 14C-Ieucine incorporation. This effect does not appear to be explicable entirely by hemodilution, since the hemoglobin concentration with halofenate was slightly higher than that with probenecid, but in view of the lowering of hemoglobin observed in both treatment groups a contributory role of hemodilution is not ruled out. Support for hemodilution as a factor is the finding that in diabetes insipidus halofenate has an antidiuretic effect 16 similar to that of clofibrate. 34 In our study, there was a small increase in percent ideal body weight in the halofenate group, rising in the final 12 wk of therapy to 3.1% above control and averaging 2.2% over the entire 48-wk treatment period. These weight changes did not differ significantly from the weight gain in the probenecid group. When the values for the 2 subjects (one diabetic) who gained more than 5% of ideal weight in the halofenate group are excluded, the percent change averaged + 1.4. When the values for the 2 subjects (one diabetic) who gained more than 5% ideal weight in the probenecid group are excluded, the percent change averaged -0.7.
An increase in body weight has been reported in outpatients taking clofibrate,l1 which has been shown not to be due to fluid retention 30 and is postulated 30 to represent increased adipose tissue mass. More study involving repeated assessment of caloric intake and energy expenditure and measurement of percent adipose mass is required to resolve the question whether and how halofenate induces weight gain in subjects at isocaloric status.
Only Morgan and co-workers 33 and Hutchinson and Wilkinson 2 1. 22 have reported on the effect of halofenate on LDH responses. They found, contrary to our detection of a significant elevation (13.3% for all study periods combined), that it did not change. LDH is found in all tissues, especially in myocardium, kidney, liver, and muscle. The mechanism for the observed increase is not yet known. Others have reported elevations in SOOP· 2, 4 and serum CPK.l, 2, 4, 21 Whether these changes represent hepatic, muscle, or other tissue response is not yet known.
In an attempt to determine why the average percent reduction in serum triglyceride concentration is smaller in this study than in many others, all relevant studies were reviewed and results tabulated to enable comparison of studies of the multiple factors. Because changes in weight can produce changes in serum triglycerides,6 cholesterol ,41 or uric acid,35 valid comparisons were possible only in studies which indicated whether weight changes occurred. Only four studies 22 , 29, 33, 36 indicated the weight status at the end of the study (all stated that there had been no weight change), but no values for weight at the close of study are given and none indicate the subject's degree of overweight. In these studies, all administered 1.0 gm/day halofenate. The duration of studies and the percent decline in serum triglycerides were: Morgan and associates,33 6 wk, 50% decrease; Ravenscroft and co-workers,36 9 days, 26% decrease; Hutchinson and colleagues,22 4 wk, 16% decrease (reported, ". . . no significant change in triglycerides due to wide range of values"); Lisch and associates,29 48 wk, 47% decline during the second 24-wk period in 6 type IV patients. Statistical analysis29 was done by means of Student's t test, with "treatment period results" compared with baseline. It is unclear whether a paired t test was used, and no allowance appears to have been made for the skewed triglyceride distribution. Nevertheless, the graphic presentation of the mean data appears significant. Our findings (see "Results" section) are likely to reveal the principal reasons for the differences reported in various studies, i.e., the importance of the percent ideal weight, serum uric acid, and alcohol intake in determining the degree of triglyceride reduction.
Only a few studies have been published which describe mechanisms by which halofenate might lower serum triglyceride concentrations. Homcy and Margolis 19 reported on the comparative effects of halofenate and clofibrate on acetate and fatty acid oxidation and on lipid and protein synthesis in isolated rat hepatocytes. Halofenate was 30 times as potent in decreasing lipid synthesis from 14C-acetate; it also inhibited 14C-leucine incorporation into protein. These workers proposed, based on earlier work, 12, 14, 20, 42, 43, 45 that displacement by the drug of fatty acid from albumin was responsible for its principal effects. Greenspan and associates 18 compared the effects of halofenate and clofibrate on lipid synthesis in isolated rat adipocytes and found these drugs to inhibit the incorporation of tagged glucose and pyruvate into adipose fatty acids. The strong tendency for halofenate to bind to albumin appears to be the basis, and possibly the sole basis, for the effects of halofenate noted in relation to thyroid hormone and related compounds,12 bilirubin 2 1. 22, 33, 40 and sulfonylureas. 25 Additional reactions which must be considered in the use of halofenate as a pharmacotherapeutic agent include the significance of its effect on serum Halofenate and probenecid 349 CPK, SGOT, and LDH, the mechanisms of its decreased beta blockade effect, 28 and the mechanism of its effect in decreasing platelet aggregation. 27 The principal contribution of our work is the demonstration of the relationship of initial percent ideal body weight to subsequent response in serum triglyceride concentration to halofenate and probenecid, and the relationship of initial serum uric acid concentration to subsequent serum triglyceride and uric acid response to halofenate and probenecid. The approach taken here is one way of considering the law of the initial value. 49 Workers undertaking similar studies of the effects of this or similar drugs should carefully evaluate the degree of overweight and of relative adipose mass and should assure that weight is kept constant and is reported in such studies. Analyses should be made of drug dosage, caloric intake, nutrient intake, and energy expenditure and their effects on serum lipids and uric acid. Only when this is done will it be possible to draw firm conclusions on the effectiveness of halofenate (or of any drug) in hyperlipidemic or hyperuricemic patients.
